Back

HUTCHMED submits US NDA for ORPATHYS and TAGRISSO lung cancer combination

  • HUTCHMED submitted a US NDA for ORPATHYS® plus TAGRISSO®.
  • The application concerns MET-driven, EGFR-mutated lung cancer.
  • The filing seeks US regulatory consideration of the treatment combination.

HUTCHMED announced the submission of a U.S. New Drug Application (NDA) for ORPATHYS® plus TAGRISSO® in MET-driven, EGFR-mutated lung cancer. The filing seeks U.S. regulatory consideration of the two-drug combination for this defined form of lung cancer.

The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.